Synaptic and Cognitive Improvements by Inhibition of 2-AG Metabolism Are through Upregulation of MicroRNA-188-3p in a Mouse Model of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Abnormal accumulation of β-amyloid (Aβ) is the major neuropathological hallmark of Alzheimer's disease (AD). However, the mechanisms underlying aberrant Aβ formation in AD remain unclear. We showed previously that inhibition of monoacylglycerol lipase (MAGL), the primary enzyme that metabolizes the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain, robustly reduces Aβ by inhibiting β-site amyloid precursor protein cleaving enzyme 1 (BACE1), a key enzyme responsible for Aβ formation. However, the molecular mechanisms responsible for suppression of BACE1 by inhibition of 2-AG metabolism are largely unknown. We demonstrate here that expression of the noncoding small RNA miR-188-3p that targets BACE1 was significantly downregulated both in the brains of AD humans and APP transgenic (TG) mice, a mouse model of AD. The downregulated miR-188-3p expression was restored by MAGL inhibition. Overexpression of miR-188-3p in the hippocampus reduced BACE1, Aβ, and neuroinflammation and prevented deteriorations in hippocampal basal synaptic transmission, long-term potentiation, spatial learning, and memory in TG mice. 2-AG-induced suppression of BACE1 was prevented by miR-188-3p loss of function. Moreover, miR-188-3p expression was upregulated by 2-AG or peroxisome proliferator-activated receptor-γ (PPARγ) agonists and suppressed by PPARγ antagonism or NF-κB activation. Reducing Aβ and neuroinflammation by MAGL inhibition was occluded by PPARγ antagonism. In addition, BACE1 suppression by 2-AG and PPARγ activation was eliminated by knockdown of NF-κB. Our study provides a novel molecular mechanism underlying improved synaptic and cognitive function in TG mice by 2-AG signaling, which upregulates miR-188-3p expression through PPARγ and NF-κB signaling pathway, resulting in suppressions of BACE1 expression and Aβ formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“5XFAD TG mice, expressing both mutant human APP(695) with the Swedish (K670N, M671L), Florida (I716V ), and London (V717I ) Familial Alzheimer’s Disease (FAD) mutations and human PS1 harboring two FAD mutations, M146L and L286V (Oakley et al., 2006), were obtained from The Jackson Laboratory (stock #006554).”
BackgroundMethodAlzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“Growing evidence suggests that miRNA-based therapies, either restoring or reversal of deregulated miRNAs expression and activity, hold great promise for clinical applications (van Rooij et al., 2012; Hydbring and Badalian-Very, 2013; Zhang et al., 2013).”
BackgroundDeciphering the Molecular Basis of Memory Failure in Alzheimer's Disease
Walsh, D. M., & Selkoe, D. J. (2004) · Neuron · doi:10.1016/j.neuron.2004.09.010 · Cited by 1,207
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., Kauppinen, S., Delacourte, A., & De Strooper, B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710263105 · Cited by 1,183 · cited 2×
“shown that expressions of miRNAs, including those targeting BACE1, are altered both in AD humans and/or animal models (Boissonneault et al., 2009; Hébert et al., 2008; Wang et al., 2008; Schonrock and Götz, 2012).”
BackgroundA Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol
Blankman, J. L., Simon, G. M., & Cravatt, B. F. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.11.006 · Cited by 1,177 · cited 4×
“Regulation of miR-188-3p expression by 2-AG is mediated by the PPAR and NF- B signaling pathway Inhibition of 2-AG metabolism by JZL184 robustly raises brain 2-AG levels and reduces AA and its derivatives (Blankman et al., 2007; Long et al., 2009a,b; Nomura et al., 2011; Piro et al., 2012).”
BackgroundInfluentialRegulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132
Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C.-F., Seeburg, D. P., Batterton, M. N., Tada, T., Dolan, B. M., Sharp, P. A., & Sheng, M. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.005 · Cited by 735 · cited 2×
“Hippocampal LTP was induced by a theta burst stimulation as described previously (Fan et al., 2010; Chen et al., 2012, 2013).”
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442 · cited 2×
“Weihong Song of the University of British Columbia) as described previously (Ly et al., 2013).”
MethodProbing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., Li, R., & Shen, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200705042 · Cited by 390 · cited 1×
“We observed that Piog or rosiglitazone (ROS), another PPAR agonist, reduced BACE1 promoter activity, whereas TNF increased it (He et al., 2007).”
Background
Cited by
An update on PPAR activation by cannabinoids
O'Sullivan, S. E. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13497 · Cited by 449
A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease
Reddy, P. H., Tonk, S., Kumar, S., Vijayan, M., Kandimalla, R., Kuruva, C. S., & Reddy, A. P. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.067 · Cited by 143
The Regulation of microRNAs in Alzheimer's Disease
Kou, X., Chen, D., & Chen, N. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00288 · Cited by 112
MicroRNAs in Alzheimer’s Disease: Function and Potential Applications as Diagnostic Biomarkers
Wei, W., Wang, Z.-Y., Ma, L.-N., Zhang, T.-T., Cao, Y., & Li, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00160 · Cited by 103
Chen, J.-J., Zhao, B., Zhao, J., & Li, S. (2017) · Neural Plasticity · doi:10.1155/2017/7027380 · Cited by 93
Metadata
- Authors
- Zhang, J., Hu, M., Teng, Z., Tang, Y.-P., & Chen, C.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2014-11-05
- Volume
- 34
- Issue
- 45
- Pages
- 14919-14933
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2000184987
- Cited by
- 138
- References
- 16
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synaptic and Cognitive Improvements by Inhibition of 2-AG Metabolism Are through Upregulation of MicroRNA-188-3p in a Mouse Model of Alzheimer's Disease. https://app.cochat.ai/papers/10.1523/jneurosci.1165-14.2014
- The paper
- Zhang, J., Hu, M., Teng, Z., Tang, Y.-P., & Chen, C. (2014). Synaptic and Cognitive Improvements by Inhibition of 2-AG Metabolism Are through Upregulation of MicroRNA-188-3p in a Mouse Model of Alzheimer's Disease. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1165-14.2014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.